Financial Performance - The company achieved an operating revenue of 925 million RMB, representing an 18.18% increase compared to the previous year [3] - The comprehensive gross profit margin was 71.31%, an increase of 1.09 percentage points year-on-year [3] - The adjusted net profit attributable to the parent company was approximately 182 million RMB, meeting the budget target for the year [3] Business Strategy - The company implemented a "3+2" market development strategy focusing on three key industries: peptides, bispecific antibodies/ADC, and blood products, while also exploring opportunities in vaccines and small nucleic acids [4] - Sales revenue from core business products, chromatography fillers and media, reached 552 million RMB, a growth of 22.57% year-on-year [4] - International business revenue was approximately 84 million RMB, showing a significant growth of about 78% [4] Research and Development - The company increased its R&D investment to 197 million RMB, an 11.12% increase from the previous year, accounting for 21.29% of the annual operating revenue [5] Profitability Improvement - Operating profit and total profit increased by 88.48% and 87.51% respectively, outpacing the growth rate of operating revenue [7] - The net profit attributable to the parent company grew by 64.18%, while the net profit excluding non-recurring gains and losses increased by 78.55% [7]

Core Viewpoint - The construction ceremony for the 200,000 liters/year biopharmaceutical separation and purification auxiliary materials project by Suzhou Saifen Technology Co., Ltd. was held, marking a significant milestone in the company's expansion and capacity enhancement in the biopharmaceutical sector [1]. Group 1: Project Details - The project will include the construction of three chromatography medium production workshops, along with supporting warehouses, tank areas, and wastewater treatment facilities, covering an area of approximately 21,000 square meters [1]. - The new project will add an annual production capacity of 200,000 liters of chromatography media, including affinity chromatography fillers, ion exchange fillers, and composite chromatography fillers [1]. Group 2: Company Performance - Saifen Technology has been actively involved in the rapid development of China's biopharmaceutical industry, accumulating over 100 application projects in various biopharmaceutical segments, including antibodies and insulin [2]. - The company reported a strong business performance since its listing on the STAR Market, achieving a revenue of 302 million yuan in the first three quarters of 2025, a year-on-year increase of 38.39%, and a net profit of 93.21 million yuan, up 71.07% [3]. Group 3: Market Context - The rapid development of the Chinese biopharmaceutical industry is highlighted by significant achievements from partners of Saifen Technology, indicating a growing demand for high-performance, large-scale, and high-quality domestic chromatography fillers [4]. - The new project will enhance the company's ability to deliver on a large scale and support the stable production and capacity growth of its partners, while also aiding in the company's strategy to expand into overseas markets [4].